HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Policy

What’s at stake in Amgen’s showdown with the FDA?

The agency accused Amgen of manipulating data for its fast-growing drug Tavneos and wants it pulled from the market, but the large pharma is digging its heels in.

By PharmaVoice · May 5, 2026 · via PharmaVoice
What’s at stake in Amgen’s showdown with the FDA?

Image: PharmaVoice

This is an aggregated industry headline. Read the full story at PharmaVoice →

Tags
policyformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
Reproductive Rights Litigation Escalates Across States Post-Dobbs
PolicyBriefing
Reproductive Rights Litigation Escalates Across States Post-Dobbs
With Roe overturned, state and federal courts are becoming the frontline in defining access to abortion and co…
May 14, 2026
Medicaid Mental Health and Substance Use: Expansion Trends and the Fiscal Pressure Ahead
PolicyKFF Health News ↗
Medicaid Mental Health and Substance Use: Expansion Trends and the Fiscal Pressure Ahead
This brief examines recent state trends in Medicaid behavioral health coverage and payment and state coverage …
May 13, 2026
STAT+: Provider, insurer groups rush to shape No Surprises Act arbitration rules
PolicySTAT News ↗
STAT+: Provider, insurer groups rush to shape No Surprises Act arbitration rules
Doctors and insurers are battling to reshape the controversial No Surprises Act arbitration process, which has…
May 11, 2026